; (10) any anticipated royalty fees from licensing to other manufacturers; and (11) with respect to the manufacturer— (A) all stock-based performance metrics used by the manufacturer to determine executive compensation over the preceding 12 months; and (B) any additional information the manufacturer chooses to provide related to drug pricing decisions. (d) Civil monetary penalties (1) Failure to submit Any manufacturer of a covered drug that fails to submit a report as required by this section, following notification by the Secretary to the manufacturer that the manufacturer is not in compliance with this section, shall be subject to a civil monetary penalty of $100,000 for each day on which the violation continues. (2) False information Any manufacturer of a covered drug that knowingly provides false information in a report under this section is subject to a civil monetary penalty in an amount not to exceed $100,000 for each item of false information. (e) Public posting (1) In general Subject to paragraph (3), the Secretary shall post each report submitted under subsection (b) on the public website of the Department of Health and Human Services no later than 30 days after the submission of the report. (2) Format The Secretary shall ensure that such reports are— (A) user-friendly to the public